Most Relevant Terms per Topic

Abstracts with Biological Entities (English) - 75 Topics / Sub-Topic Model 15

Topic 1 Topic 2 Topic 3 Topic 4 Topic 5 Topic 6 Topic 7 Topic 8 Topic 9 Topic 10 Topic 11 Topic 12 Topic 13 Topic 14 Topic 15
1 drugs antiviral in vitro screening coronavirus peptides delivery influenza inhibitors ebola hepatitis agonists JEV UPS mabs
2 clinical viral vitro discovery sars-cov-2 antimicrobial rnai M2 norovirus EBOV DNA diabetes RSV ubiquitin monoclonal
3 drug viruses infection drug COVID-19 natural sirna IAV protease GS-5734 simplex derivatives diarrhea IFN antibodies
4 diseases virus vivo virtual sars-cov peptide interference H5N1 molecule ebola virus HCV ferroquine encephalitis oncolytic HCV
5 development host effect compounds SARS amps antisense H1N1 enzyme EVD HRV antimalarials assay proteasome CQ
6 therapeutic replication in vivo docking syndrome natural products gene pandemic 3clpro fatality cytomegalovirus malaria VEEV dubs monoclonal antibodies
7 review antiviral drugs activity lead mers-cov products sirnas neuraminidase small molecule niv HCMV effects SCV signaling HCQ
8 studies development cells virtual screening respiratory bacteria nucleic avian inhibitor africa infections antimalarial aureus CEP mab
9 current viral infections chloroquine silico coronaviruses activities drug delivery oseltamivir x-ray favipiravir herpes niclosamide rotavirus oncolytic viruses antibody
10 trials infections results in silico middle antibiotics RNA seasonal proteases fever HBV HCT fda-approved cancer p7
11 recent RNA model drug candidates east bacterial oligonucleotides neuraminidase inhibitors gastroenteritis conducted HEV lymphatic EV71 stroke escape
12 therapies antivirals treatment target 2019 marine rna interference influenza viruses rdrp amodiaquine nucleoside anthelmintic S. DUB htas
13 patients human inhibitory chemical acute respiratory syndrome antibiotic systems anti-influenza active site case fatality hiv infections NM CPV serms cocktail
14 animal antiviral agents showed design remdesivir sources mirnas influenza a virus scaffolds nipah NS5B p-pd SMA 1996 antibody-based
15 clinical trials proteins study computational MERS microbial targeted amantadine protease inhibitors BCX4430 syncytial antimalarial drugs cryptosporidiosis tumor mutants
16 efficacy entry inhibited drug discovery china resistance antisense oligonucleotides channel macrocyclic nvis common lipid growth pharmacological epitopes
17 treatment drugs antiviral protein 2019-ncov properties ARDS H3N2 noroviruses arenavirus analogues effects of cryptosporidium antitumor genotype
18 approaches targets concentrations identification acute organisms vectors diphyllin structure-based countermeasures ii metabolism breast anti-cancer SL
19 disease agents demonstrated pharmacophore severe fungi material pandemics small propose herpes simplex virus side s. aureus ifn-ω positions
20 approved ZIKV mouse targets emetine activity interfering influenza virus substrate outbreaks cold dual children parkinson microbial diseases
21 treat viral diseases inhibition HTS cov plants users influenza virus infection site BSL-4 EV-D68 AD library enzymes cyclophilin
22 promising resistance antiviral activity high-throughput middle east respiratory syndrome coronavirus extracts SUPPLEMENTARY hemagglutinin 3CL DEF201 i.e. immunomodulators japanese immunity genotypes
23 provide HIV effective molecular pandemic antimicrobial peptides authorized SP-D structure SFTSV half bcl-2i SMN cellular DMD
24 models immunodeficiency virus process spread plant supplementary HA acute gastroenteritis tpcs chronic tetracyclines ouabain bortezomib unborn
25 potential cycle agent drug design drugs venoms version influenza pandemic picornavirus containment hepatitis b plasmodium bactericidal cancer therapy anti-adhesion
26 treating targeting identified throughput ritonavir scorpion online export anti-norovirus boosted HSV NAFLD SMD1168H-TOPOI modulators daas
27 action broad-spectrum nitazoxanide affinity lopinavir environment facilitate 2009 indole biosafety dna viruses melanoma poliovirus kinases GT3
28 mortality viral replication recombinant ligand mpro antifungal systemic influenza virus infections design SFTS © glucose closantel receptor GT4
29 treatments vaccines ribavirin drug discovery process acute respiratory syndrome coronavirus antimicrobial activity therapeutic AP3 small molecule inhibitors proofreading iii macrophages parasite ubiquitin pathway interferon-free
30 research life concentration libraries proteinase antibacterial therapy v-atpase norovirus infection west africa ENF DPP-4 enterovirus 71 type i ifn immunoglobulin
31 including infection cell structure hcov candida online version drug-resistant structural haemorrhagic GA side effects camptothecin innate immunity immune
32 advances important CHIKV candidates spike lectins barriers T20 replicon ebola virus disease ARB swine ML-HSA S6 total
33 agents factors FCV active middle east respiratory syndrome antimicrobial drugs cpps drug-resistant viruses WNV post-exposure ribavirin MS multiplication proteasome inhibitors transduced
34 overview polymerase μm based main due INFORMATION shedding SERT RVFV chronic hepatitis b enterocyte equine activators pre-exposure
35 made viral proteins reduction compound mers-cov. found vascular mtb crystal arenaviruses CMV rheumatoid anti-ev71 ifn‐β government
36 numerous human immunodeficiency virus feline hits homology natural product liposomes DP2392-E10 crystallography case periodicals anti-trypanosomal TI OV ebovs
37 effective target test identified wuhan antimicrobial activities organs viruses JNK chlorpromazine wiley GALT platelet FAN IND
38 evidence treatment antiviral effect 3D rapidly SM21 directed hiv-infected catalytic cifn-α formally steatosis sitafloxacin TET interferon-based
39 success genetic load approach protease eval418 lung epithelial norovirus 3cl protease MHV res lupus drug library dopamine u.s. food and drug administration
40 — zika effects programs anti-coronavirus gossypol targeting influenza infection ncrna nipah virus immediate-early apoptosis projects tumors cyclophilin inhibitors
41 past dengue griffithsin learning sars-cov infection present target hiv-1 strains focused curve med rheumatoid arthritis EV-71 parkinson’s disease invariant
42 effects genome prevented secondary mers-cov infection infectious expression bafilomycin genus ebolavirus conjugate tβ4 retrocyclins RAS HDL
43 safety inhibitors therapeutic experimentally CVL218 agents vehicles pandemic influenza βglu ntds VZV activating breast cancer kinase biothreat
44 summarize antiviral therapeutics vero identify sars-cov. polyether nucleic acids iavs viral protease TPC2 colds aips 71 anticancer federal
45 molecules play replication billion spreading antiviral properties therapeutic molecules slices dipeptidyl LASV recipients tα1 reporter hematological couples
46 repurposed enveloped disease optimized hiv-1 protease inhibitors pomegranate ill PAM SP600125 dosed no. GLP-1 hit CXCR4 REGN3051
47 approval viral life cycle ifn-α chemical libraries 2020 scorpions deliver TCAD probiotics lethal hepatitis c virus body weight motor endolysosomal adhesins
48 clinical studies potential FIP NMR interactome efflux designed verdinexor sars-cov-2 3clpro rates GS‐6620 poly screening ischemic REGN3048
49 context antiviral compounds cytotoxicity active compounds ivermectin ctry2459 messenger classes norovirus 3c-like protease severe vi hopping strain ovs AO
50 benefits host factors symptoms protein targets signatures natural sources ribozymes strains norovirus infections outbreak cidofovir absorption high-throughput radiation restore